CA2774274A1 - Diagnostic agent for parkinson's disease - Google Patents
Diagnostic agent for parkinson's disease Download PDFInfo
- Publication number
- CA2774274A1 CA2774274A1 CA2774274A CA2774274A CA2774274A1 CA 2774274 A1 CA2774274 A1 CA 2774274A1 CA 2774274 A CA2774274 A CA 2774274A CA 2774274 A CA2774274 A CA 2774274A CA 2774274 A1 CA2774274 A1 CA 2774274A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- alpha
- synuclein
- syn
- oligomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 158
- 239000000032 diagnostic agent Substances 0.000 title description 2
- 229940039227 diagnostic agent Drugs 0.000 title description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 70
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 14
- 208000024891 symptom Diseases 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 11
- 239000004090 neuroprotective agent Substances 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 3
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 3
- 230000001910 anti-glutamatergic effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- 229960003624 creatine Drugs 0.000 claims description 3
- 239000006046 creatine Substances 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 3
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 3
- 229960004023 minocycline Drugs 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 3
- 229960003089 pramipexole Drugs 0.000 claims description 3
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical group C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 3
- 229960000245 rasagiline Drugs 0.000 claims description 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001879 ropinirole Drugs 0.000 claims description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 3
- 229960003946 selegiline Drugs 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001228 trophic effect Effects 0.000 claims description 3
- 241000352333 Amegilla alpha Species 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 11
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 206010044565 Tremor Diseases 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 8
- 206010006100 Bradykinesia Diseases 0.000 description 7
- 208000006083 Hypokinesia Diseases 0.000 description 7
- 208000002740 Muscle Rigidity Diseases 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102100026882 Alpha-synuclein Human genes 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 2
- 206010050515 Hyposmia Diseases 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 2
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000025535 REM sleep behavior disease Diseases 0.000 description 2
- 206010071390 Resting tremor Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 235000019559 hyposmia Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010001540 Akathisia Diseases 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 101710107142 Dopamine receptor 2 Proteins 0.000 description 1
- 101710107139 Dopamine receptor 4 Proteins 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 206010056696 Gaze palsy Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010057333 Micrographia Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000002192 Parkinson disease 3 Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 101710102828 Vesicle-associated protein Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000031326 autosomal dominant parkinson disease 3 Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0916264.5 | 2009-09-16 | ||
| GB0916264A GB0916264D0 (en) | 2009-09-16 | 2009-09-16 | Diagnostic agent for parkinson's disease |
| GB201011045A GB201011045D0 (en) | 2010-06-30 | 2010-06-30 | Diagnostic agent for parkinsons disease |
| GB1011045.0 | 2010-06-30 | ||
| PCT/GB2010/001723 WO2011033252A1 (en) | 2009-09-16 | 2010-09-13 | Diagnostic agent for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2774274A1 true CA2774274A1 (en) | 2011-03-24 |
Family
ID=42940401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2774274A Abandoned CA2774274A1 (en) | 2009-09-16 | 2010-09-13 | Diagnostic agent for parkinson's disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120190652A1 (enExample) |
| EP (1) | EP2478375B1 (enExample) |
| JP (1) | JP5778678B2 (enExample) |
| CA (1) | CA2774274A1 (enExample) |
| ES (1) | ES2541213T3 (enExample) |
| WO (1) | WO2011033252A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201011420D0 (en) * | 2010-07-06 | 2010-08-18 | United Arab Emirates Universit | Method for diagnosis |
| GB201411616D0 (en) * | 2014-06-30 | 2014-08-13 | Cambridge Entpr Ltd | Diagnosis and treatment of neurodegenerative disorders |
| KR101860566B1 (ko) * | 2016-12-06 | 2018-05-23 | 경희대학교 산학협력단 | 파킨슨병을 진단하기 위한 정보제공방법 |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| CN111024843B (zh) * | 2019-12-18 | 2022-06-21 | 大连医科大学附属第一医院 | 用于诊断帕金森病的联合标志物及检测试剂盒 |
| CN114047281B (zh) * | 2022-01-04 | 2022-03-25 | 宝枫生物科技（北京）有限公司 | 帕金森病的生物标志物的组合及其应用 |
| CN114019079B (zh) * | 2022-01-04 | 2022-03-18 | 宝枫生物科技（北京）有限公司 | 诊断帕金森病的生物标志物及其应用 |
| CN119310290A (zh) * | 2024-11-28 | 2025-01-14 | 香港中文大学（深圳） | 一种帕金森病的诊断标志物及其应用和杂聚体检测方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1095278B1 (en) * | 1998-07-03 | 2005-12-07 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| US20050202508A1 (en) * | 2003-11-12 | 2005-09-15 | Pasinetti Guilio M. | Biomarker for Parkinson's disease |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| GB0716885D0 (en) * | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
-
2010
- 2010-09-13 CA CA2774274A patent/CA2774274A1/en not_active Abandoned
- 2010-09-13 JP JP2012529334A patent/JP5778678B2/ja not_active Expired - Fee Related
- 2010-09-13 US US13/394,358 patent/US20120190652A1/en not_active Abandoned
- 2010-09-13 WO PCT/GB2010/001723 patent/WO2011033252A1/en not_active Ceased
- 2010-09-13 EP EP10755214.3A patent/EP2478375B1/en active Active
- 2010-09-13 ES ES10755214.3T patent/ES2541213T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2541213T3 (es) | 2015-07-16 |
| WO2011033252A1 (en) | 2011-03-24 |
| US20120190652A1 (en) | 2012-07-26 |
| JP2013504766A (ja) | 2013-02-07 |
| EP2478375B1 (en) | 2015-04-15 |
| EP2478375A1 (en) | 2012-07-25 |
| JP5778678B2 (ja) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2478375B1 (en) | Diagnostic agent for parkinson's disease | |
| KR102384115B1 (ko) | 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법 | |
| AU2009282117B2 (en) | Biomarker detection process and assay of neurological condition | |
| US9625460B2 (en) | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers | |
| US8778334B2 (en) | Method of identifying whether or not an individual has Parkinson's Disease rather than another neurodegenerative disease | |
| JP7495878B2 (ja) | 神経変性状態を処置するための医薬を開発するための方法 | |
| CA2784935A1 (en) | Biomarkers | |
| US20130131111A1 (en) | Nmn modulators for the treatment of neurodegenerative disorders | |
| WO2020123884A1 (en) | Neuron-derived exosomes and their biomarkers for the diagnosis, prognosis, and treatment of traumatic brain injury and alzheimer's disease | |
| US10393760B2 (en) | Specialized excitatory synaptic protein biomarkers of plasma neuronal exosomes for prediction and staging of Alzheimer's disease | |
| IL208134A (en) | Methods and Kits for Differential Diagnosis of Alzheimer's Disease vs. Frontotemporal Dementia | |
| Costa et al. | Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease | |
| KR20220163936A (ko) | 신경퇴행성 병태의 바이오마커로서 키나제 | |
| US20250067731A1 (en) | Serological assays for parkinson's disease | |
| JP6290398B2 (ja) | 多発性硬化症（ｍｓ）を監視する方法および予測キット | |
| US20240264177A1 (en) | Biomarker detection process and assay of neurological condition | |
| JP7144007B2 (ja) | 血液検体を用いたｍｃｉ及び認知症の補助診断方法 | |
| CN111323597A (zh) | 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法 | |
| WO2012137502A1 (ja) | アルカデインペプチド切断物による認知症又はアルツハイマー病の診断方法又は予後予測方法 | |
| WO2023174946A1 (en) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease | |
| HK40083580A (en) | Protein markers for assessing alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150826 |
|
| FZDE | Dead |
Effective date: 20180611 |